Internal Medicine, Pulmonary Disease · Rio Piedras, PR
NPI
1255344859
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
369 Ave. de Diego, 308 Torre San Francisco
Rio Piedras, PR, 00924
Phone (787) 767-6777
Medicare paid, 2024
$21K
448 services
Medicare patients, 2024
45
Average age 75
Drug cost, 2024
$1.8M
6,102 prescriptions
Company payments, 2025
$878
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Luis F Nieves Garrastegui was code 99214 (office e&m - established), 76 times for 37 patients. In total Luis F Nieves Garrastegui billed 448 services in 15 codes, and Medicare paid $21K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-08-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 76 | 37 | $96.51 | $7,335 |
| 94664 E&M - Miscellaneous | Office | 74 | 44 | $13.50 | $999 |
| 94060 Pulmonary Function Testing | Office | 58 | 43 | $29.77 | $1,727 |
| 94727 Pulmonary Function Testing | Office | 57 | 43 | $35.06 | $1,998 |
| 94729 Pulmonary Function Testing | Office | 56 | 43 | $44.51 | $2,493 |
| 94200 Pulmonary Function Testing | Office | 37 | 29 | $11.79 | $436 |
| 94726 Pulmonary Function Testing | Office | 35 | 24 | $42.47 | $1,487 |
| 94375 Pulmonary Function Testing | Office | 16 | 14 | $30.67 | $491 |
By year: 2022 $21K for 383 services; 2023 $22K for 444 services; 2024 $21K for 448 services.
Medicare prescription drug claims, 2024
In 2024, the drug Luis F Nieves Garrastegui prescribed most often to Medicare patients was Montelukast Sodium, with 848 prescriptions and refills. In total Luis F Nieves Garrastegui wrote 6,102 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 848 | 1,029 | 253 | $8,292 |
| Levalbuterol Tartrate Hfa Levalbuterol Tartrate | 651 | 776 | 373 | $38K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 643 | 653 | 139 | $429K |
| Spiriva Respimat Tiotropium Bromide | 556 | 576 | 160 | $306K |
| Fluticasone Propionate Generic | 478 | 506 | 197 | $7,529 |
| Breo Ellipta Fluticasone/Vilanterol | 468 | 477 | 115 | $196K |
| Levocetirizine Dihydrochloride Generic | 432 | 443 | 148 | $4,386 |
| Desloratadine Generic | 282 | 282 | 95 | $6,559 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 227 | 239 | 56 | $33K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 214 | 230 | 138 | $10K |
| Famotidine Generic | 193 | 197 | 112 | $1,062 |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 174 | 179 | 33 | $87K |
| Azithromycin Generic | 166 | 166 | 138 | $1,373 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 89 | 94 | 34 | $19K |
| Fluticasone Propionate Hfa Fluticasone Propionate | 68 | 75 | 36 | $16K |
Brand drugs: 3,085 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Luis F Nieves Garrastegui $878 ($878 in general payments such as food, travel and fees) from 8 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $269.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 3 | $269 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $200 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $106 |
| Jazz Pharmaceuticals Inc. JAZZ | 2 | $83.7 |
| GlaxoSmithKline, LLC. GSK | 3 | $75 |
| Merck Sharp & Dohme LLC MRK | 2 | $65.12 |
| Amgen Inc. AMGN | 2 | $54 |
| Eli Lilly Export S.A. Puerto Rico Branch LLY | 1 | $25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.